Dietzschold Bernhard, Faber Milosz, Schnell Matthias J
Department of Microbiology and Immunology, Thomas Jefferson University, 1020 Locust Street, Suite 459, Philadelphia, PA 19107, USA.
Expert Rev Vaccines. 2003 Jun;2(3):399-406. doi: 10.1586/14760584.2.3.399.
Despite significant progress in improving the pre- and postexposure prophylaxis of human rabies, the development of better and more cost-effective vaccines and antiviral therapeutics remains a major goal for the treatment of human rabies, the control of animal rabies and particularly for the eradication of rabies virus reservoirs in terrestrial wildlife. In this review, we discuss the structural requirements for an effective rabies vaccine, as well as new strategies currently in use for the development of safer and more potent rabies vaccines for rabies prophylaxis and eradication. Finally, we discuss new immune therapeutics aimed at replacing the conventional administration of antirabies immunoglobulin used in rabies post-exposure prophylaxis in humans.
尽管在改善人类狂犬病暴露前和暴露后预防方面取得了重大进展，但开发更好且更具成本效益的疫苗和抗病毒疗法仍然是治疗人类狂犬病、控制动物狂犬病，尤其是根除陆地野生动物中狂犬病病毒宿主的主要目标。在本综述中，我们讨论了有效狂犬病疫苗的结构要求，以及目前用于开发更安全、更有效的狂犬病疫苗以进行狂犬病预防和根除的新策略。最后，我们讨论了旨在取代人类狂犬病暴露后预防中常规使用的抗狂犬病免疫球蛋白给药方式的新型免疫疗法。
